Marinomed Biotech AG Carragelose Strategic Options 2023

Marinomed Biotech AG presents its strategic evaluation of the Carragelose portfolio, a premium medical device business operating through B2B white label licensing. The company highlights its strength in IP generation and product development, with Carragelose products sold in over 40 countries and self-sustaining revenue growth. The presentation outlines growth potential through ongoing licensing negotiations and newly developed products.